Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060957 · ClinicalTrials.gov registry record · Phase 2

Botulinum Toxin (BOTOX) for Cerebral Palsy

A Phase 2 study of Cerebral Palsy and Muscle Spasticity, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT00060957 is a Phase 2 study of Cerebral Palsy and Muscle Spasticity that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 40 participants, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00060957, a Phase 2 study of Cerebral Palsy and Muscle Spasticity, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children. Botulinum toxin is a naturally occurring bacterial toxin (botulinum toxin) that inactivates certain parts of muscles.

Interventions

  • DRUG Botulinum toxin type A

Study Locations (1)

Washington

  • Children's Hospital and Regional Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1997-07
Phase Phase 2

What the Registry Record Tells You About NCT00060957

The ClinicalTrials.gov registry entry for NCT00060957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (83% lower). The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin type A is the first listed.

NCT00060957 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00060957 about?

NCT00060957 is a clinical study titled "Botulinum Toxin (BOTOX) for Cerebral Palsy". This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children. Botulinum toxin is a naturally occurring bacterial toxin (botulinum toxin) that inactivates certain parts of muscles.

What is the current status of trial NCT00060957?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1997-07.

What conditions does trial NCT00060957 study?

This clinical trial studies the following conditions: Cerebral Palsy, Muscle Spasticity.

What interventions are being tested in trial NCT00060957?

The interventions under investigation include: Botulinum toxin type A (DRUG).

Who is sponsoring clinical trial NCT00060957?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00060957 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.